Employer Readiness for COVID-19 Vaccine
Moderators & participating panelists

Michael Thompson
President & CEO
National Alliance of Healthcare Purchaser Coalitions

Mohannad Kusti, MD
Regional Medical Director for Pivot Onsite Innovations
Medical Director for PBGH Coalition

Panelists

• Scott Conard, MD
Converging Health

• Andrea Dowdy, MD
State of Tennessee

• James Gelfand
The ERISA Industry Committee (ERIC)

• Arnie Joseph
Chroma Health
Vaccination Update – October, 2020

- 44 Vaccines in clinical trials on humans
- At least 92 preclinical vaccines are under investigation in animals
- 4 Vaccines are approved for limited use in other parts of world
- 5 Vaccines in U.S. Phase 3 Trials
4 Vaccines apparently approved for limited use in other parts of world

1. CanSino Biologics:
   - Running Phase 3 trials in a number of countries, including Saudi Arabia, Pakistan and Russia
   - Subjects will undergo for at least six months.
   - Chinese health official has publicly pledged that an effective coronavirus vaccine will be available by the end of the year.

2. Gamaleya Research Institute (part of Russia’s Ministry of Health)
   - Putin announced that Russian regulator had approved the vaccine, renamed Sputnik V, before Phase 3 trials had begun.
   - Russia later clarified approval was “conditional registration certificate” (depend on positive results from Phase 3 trials)
   - Russia negotiated agreements to supply the vaccine to countries including Brazil, Mexico and India.

3. Wuhan Institute of Biological Products developed Sinopharm.
   - Launched Phase 3 trials in the United Arab Emirates, Peru and Morocco, some participants experience fevers & other side effects.
   - The government gave its approval to inject hundreds of thousands of people with its two experimental vaccines.
   - On Sept. 14, the U.A.E. gave emergency approval for Sinopharm’s vaccine to use on health care workers.

4. Chinese company Sinovac Biotech is testing a vaccine called CoronaVac.
   - Launched a Phase 3 trial in Brazil, Indonesia, and Turkey, China gave vaccine an emergency approval for limited use in July.
   - Agreement to supply Indonesia with at least 40 million doses by March 2021.
   - Planning on worldwide distribution of the vaccine in early 2021 — including the United States.
5 Vaccines in Phase 3 Clinical Trials in U.S.

1. **Moderna** ($1 billion US Support) – In July, Moderna lost a patent dispute over some of their vaccine technology.
   - It may take till the end of 2020 or early 2021 to reach the necessary numbers.

2. **BioNTech with Pfizer, and Fosun Pharma**: ($1.9 billion contract with US for 100 Million doses delivered by December 2020 and the option to acquire 500 million more doses).
   - Pfizer expects to manufacture over 1.3 billion doses of their vaccine worldwide by the end of 2021.

3. **Johnson & Johnson** developed a vaccine (U.S. to pay $1 billion for 100 million doses if the vaccine is approved).
   - The company is aiming for production of at least a billion doses in 2021.

4. **AstraZeneca and the University of Oxford**: ($1.2 billion in U.S. support).
   - On Sept. 6, halted global trials to investigate one volunteer, who developed a form of inflammation called transverse myelitis. Within a week, the trials resumed.
   - As of now, the United States is still keeping its trial on pause as the F.D.A. investigates.

5. **Novavax**: The Coalition for Epidemic Preparedness Innovations ($1.6 billion in U.S. support).
   - Could potentially deliver results by the start of 2021. Expects to deliver 100 million doses for use in U.S. by the first quarter of 2021.
CDC Covid-19 Vaccination Program Interim Playbook

• First detailed public guidance on how future vaccinations will be distributed in U.S. – 57 pages

• Focus on local “Jurisdictions” - plan for a phased approach
  • Phase I
    • focus on providing access to critical populations – first, health care personnel, immediately followed by high risk populations, and other essential workers
    • Identify a limited number of participating providers to be selected based on criteria outlined below.
    • Manage cold-supply chain requirements
  • Phase 2,
    • Broaden focus on “ensuring access to vaccine for critical populations who were not yet vaccinated as well as for the general population.”
    • Expand the network of providers able to administer vaccinations.
    • Work with stakeholders, including employers, to identify critical workers who may be able to access the vaccine before the general population (pp. 14-16).
  • Phase 3 – Steady state
# Covid-19 Vaccination will require a phased approach

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially Limited Supplies Available</td>
<td>Large Number of Doses Available</td>
<td>Continued Vaccination, Shift to Routine Strategy</td>
</tr>
</tbody>
</table>

**Phase I**
- Supply may be constrained
- Tight focus on vaccine administration
- Administer vaccine in closed settings to priority populations:
  - 1-A Healthcare workers likely to be exposed
  - 1-B Other essential workers
  - 1-B Those most at risk of severe illness including those over age 65

**Phase II**
- Likely sufficient supply to meet demand
- Use a broad provider network to distribute vaccine
  - Healthcare settings
  - Commercial sector (eg Retail Rx)
  - Public health venues
- Expand beyond initial populations
  - Remainder of Phase I
  - Critical Populations
  - General Population

**Phase III**
- Likely sufficient supply
- Open access to vaccinations
- Administer through additional private partner sites
- Maintain public health sites where required

Potential employer readiness consideration

• Timing of approved and available vaccine
• Public health relationships
• Advocacy for priority workers
• Cost of vaccine
• Worker trust and readiness for vaccine
• Potential access to and distribution of vaccine (2 doses)
• Contingency planning
• Other
Open Panel Discussion

Michael Thompson
National Alliance of Healthcare Purchaser Coalitions

Mohannad Kusti, MD
Regional Medical Director for Pivot Onsite Innovations
Medical Director for PBGH Coalition

Scott Conard, MD
Converging Health

Andrea Dowdy
State of Tennessee

James Gelfand
The ERISA Industry Committee (ERIC)

Arnie Joseph
Chroma Health
Registration now open!

Organizations participating include:
• American Academy of Family Physicians
• American Health Policy Institute
• Boeing
• City of Miami
• General Motors
• News Corp
• Rice University
• The Walt Disney Company
• ...And more!